QT Changes in Geriatric Patients: a Comparison of Spinal and General Anesthesia

April 16, 2024 updated by: Sinan Uzman, Haseki Training and Research Hospital

QT interval, defined as the time between the beginning of the QRS complex and the end of the T wave in electrocardiography (ECG), is an indicator of depolarization and repolarization of the myocardium.11 Prolongation of the heart rate corrected QT (QTc) interval reflects electrical instability of ventricles and is associated with life-threatening ventricular arrhythmias, including torsade de pointes, ventricular fibrillation and sudden cardiac death.

Spinal anesthesia can cause profound prolongation of the QTc interval due to disparity between lumbar and thoracic sympathetic activity following subarachnoid block. Meanwhile inhalational anesthetics, sevoflurane, isoflurane, and desflurane are known to prolong QTc interval and intravenous anesthetics such as propofol, thiopental, etomidate and ketamin can also cause remarkable prolongation of the QTc interval. Moreover laryngoscopy and intubation may contribute to prolongation of the QTc interval because of the sympathetic stimulation.

Over the years it has been occurred an increase in the proportion of elderly population requiring surgical anesthesia. The incidence of ventricular arrhythmias increases in advancing age even in the absence of underlying heart disease and elderly patients have reduced physiological functions and poor tolerance to anesthesia. However the choice of anesthesia type is critical in this population.

To the best of knowledge, there was no published study to compare spinal anesthesia and inhalational anesthesia in elderly patients with regard to the QT interval changes. Investigators aimed to investigate the effects of spinal anesthesia on QT, QTc intervals and to compare general anesthesia with sevofluran in elderly patients.

Study Overview

Status

Completed

Detailed Description

Investigators designed a prospective, randomized trial to compare spinal and general anesthesia in elderly patients on the effects of QT interval changes. The study protocol was approved by the Health Science University Haseki Training and Research Hospital Ethics Committee, Istanbul, Turkey (date: 03/29/2023 and number: 44-2023). This study was conducted according to the Declaration of Helsinki, and written informed consent was obtained from all patients. The study was performed at a tertiary referral hospital with 700 beds in Istanbul, Turkey between 03/29/2023-05/29/2023.

The patients who will undergo lower abdominal or extremity surgery and urological surgery older than 65 years will be included in this study. The exclusion criteria are as follows: any preoperative ECG abnormalities, QTc interval > 440 ms, family history of long QT syndome, use of any medications known to affect the QTc interval, serum electrolyte abnormalities, any contraindications for spinal anesthesia (e.g. coagulation disorders), unstable angina pektoris, chronic obstructive pulmonary disease, hepatic or renal failure, American Society of Anesthesiologists (ASA) physical classification status > III, pregnancy and obesity (BMI > 30).

Participants will be divided into two groups: the spinal anesthesia (group S) and general anesthesia (group G). Randomization and group allocations will be performed by a researcher who did not participate the collection of data.

In the preoperative care unit all patients will receive 10 ml/kg Ringer's lactate solution via a peripheral vein over 30 minutes. In the operating room premedication will be obtained with 0.015 mg/kg of midazolam and 1 µg/kg fentanyl intravenously.

In group G, a 2.0 mg/kg propofol injection will be used for the induction of anesthesia and facilitating of endotracheal intubation was provided with 0.6 mg/kg rocuronium. After the intubation the patients will be ventilated with a 6-8 ml/kg of tidal volume in volume control ventilation (VCV) mode with an anesthesia machine (Dräger Primus, Dräger Medical Systems, Inc. Danvers, MA, USA). Frequency of respiration will be adjusted to maintain PET CO2 at 32-36 mm Hg. Maintenance of anesthesia will be provided with sevoflurane (1.5-2%) in an oxygen-air mixture (FiO2 = 0.4) and 0.015 mg/kg rocuronium as needed. At the end of the surgery residual neuromuscular block will be antagonized with 4 mg/kg sugammedex.

In group S, spinal anesthesia will be performed in the sitting position at the level of L3-4 or L4-5 using a 25-gauge Whitacre (pencil point) spinal needle after the obtaining strict sterile conditions and local anesthesia with intradermal lidocaine hydrochloride 1%. Hyperbaric bupivacaine (Marcaine Spinal 0.5% Heavy; AstraZeneca, Turkey) 3-4 mL of 0.5% will be injected to the subarachnoid space with the observation of cerebrospinal fluid outflow. The patient was placed in the supine position immediately after drug injection. Dermatomal level of sensorial block will be evaluated with pinprick test and modified Bormage scale was used to assess motor blockade. Surgery will be allowed after the achievement of sensorial block at the T10 level.

Monitoring and data collection Non-invasive blood pressure, heart rate (HR), peripheral oxygen saturation (SpO2) and continuous ECG monitorization will be obtained for all patients throughout the study via Mindray Bene View T8 (Shenzhen Mindray Bio-Medical Electronics Co., LTD, PR China. The QT interval will be measured automatically in lead II and calculation of the QTc interval was also achieved automatically with using Bazett's formula (QTc=QT/radqRR(sec)) from ECG monitorization. QT and QTc intervals will be measured and recorded in the following manner: before the anesthesia induction or subarachnoid injection (in group S), 1, 5, 10 minute after after endotracheal intubation or subarachnoid injection (in group S), and immediately after surgery. Presence of arrhythmia will also be recorded.

Patient characteristics including age, gender, height, weight, body mass index (BMI), comorbidity, ASA physical status classification and duration of surgery will be recorded. Moreover maximum sensory block level and motor block recovery time will be investigated in the group S. Also all cardiopulmonary adverse events will be evaluated including hypotension (decrease in mean blood pressure > 20%), bradycardia (HR < 50 beats/min) and hypoxemia (SpO2 < 90%).

Statistical analysis SPSS software package for Windows (Statistical Package for Social Sciences, version 22.0, SPSS Inc., Chicago, Illinois, USA) will be used for statistical analysis of study data. Quantitative variables were emitted as mean ± standard deviation (SD), whereas categorical variables as number of patients and percentage. Quantitative variables will be evaluated for distribution normality using the Kolmogorov-Smirnov/Shapiro-Wilk's test and independent student's t-test will be used to compare normally distributed variables between groups. To compare categorical variables chi-square or Fisher's exact test will be used. QT and QTc intervals within groups will be investigated with repeated measures analysis of variance and post hoc multiple comparisons will be performed by Bonferroni test. Sample size calculation was based on QTc interval. Based on a previous study, QTc interval was found 397.3±27.4 msec after spinal anesthesia in non-geriatric patients. Power analysis with α = 0.05 and β = 0.2 to detect an increase of at least 20 msec in QTc interval revealed that a min of 28 patients should be included in each group. A p value < 0.05 was considered to show a statistically significant result.

Study Type

Interventional

Enrollment (Actual)

58

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey
        • Health Science University, Haseki Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • patients who scheduled lower abdominal or extremity surgery and urological surgery older than 65 years were enrolled to the study.

Exclusion Criteria:

  • any preoperative ECG abnormalities, QTc interval > 440 ms, family history of long QT syndome, use of any medications known to affect the QTc interval, serum electrolyte abnormalities, any contraindications for spinal anesthesia (e.g. coagulation disorders), unstable angina pektoris, chronic obstructive pulmonary disease, hepatic or renal failure, American Society of Anesthesiologists (ASA) physical classification status > III, pregnancy and obesity (BMI > 30).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: spinal anesthesia
patients who scheduled lower abdominal or urological surgery under spinal anesthesia older than 65 years
measuring of QT and QTc on ECG
Other: general anesthesia
patients who scheduled lower abdominal or urological surgery under general anesthesia older than 65 years
measuring of QT and QTc on ECG

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
QTc interval
Time Frame: before anesthesia induction or spinal anesthesia; 1, 5 and 10 minutes after endotrakeal intubation or spinal anesthesia; after extubation or surgery
QTc interval on ECG calculated with Bazzets formula
before anesthesia induction or spinal anesthesia; 1, 5 and 10 minutes after endotrakeal intubation or spinal anesthesia; after extubation or surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
QT
Time Frame: before anesthesia induction or spinal anesthesia; 1, 5 and 10 minutes after endotrakeal intubation or spinal anesthesia; after extubation or surgery
the time between the beginning of the QRS complex and the end of the T wave in electrocardiography
before anesthesia induction or spinal anesthesia; 1, 5 and 10 minutes after endotrakeal intubation or spinal anesthesia; after extubation or surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: sinan uzman, Assoc. Prof., Health Science University Haseki Training and Research Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 29, 2023

Primary Completion (Actual)

May 29, 2023

Study Completion (Actual)

May 29, 2023

Study Registration Dates

First Submitted

March 22, 2024

First Submitted That Met QC Criteria

April 16, 2024

First Posted (Actual)

April 19, 2024

Study Record Updates

Last Update Posted (Actual)

April 19, 2024

Last Update Submitted That Met QC Criteria

April 16, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected IPD

IPD Sharing Time Frame

Beginning 9 months and ending 36 months following article publication.

IPD Sharing Access Criteria

Proposals should be directed to drsinanuzman@yahoo.com

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sevoflurane

Clinical Trials on QT and QTc interval

Subscribe